Trials / Completed
CompletedNCT05778864
A Study of LY3473329 in Participants With Impaired and Normal Renal Function
Pharmacokinetics of LY3473329 Following Oral Administration in Participants With Renal Impairment Compared With Participants With Normal Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to assess the amount of study drug (LY3473329) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3473329 will also be evaluated in these participants. The study will last up to 8 weeks including screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3473329 | Administered orally. |
Timeline
- Start date
- 2023-03-17
- Primary completion
- 2024-09-06
- Completion
- 2024-09-06
- First posted
- 2023-03-21
- Last updated
- 2024-10-28
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05778864. Inclusion in this directory is not an endorsement.